Revelation Biosciences, Inc. develops therapeutic solutions focused on inflammation management. Its primary product, Gemini, is an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD®) designed to reduce inflammation-related damage by reprogramming the innate immune system. The company is engaged in clinical studies to evaluate the efficacy of its products in treating conditions such as acute kidney injury.
